Additional Information
| Product Name: | Ixazomib (MLN-2238) |
|---|---|
| Also Known As: | [(1R)-1-[[(2S,3R)-3-hydroxy-2-[(6-phenylpyridine-2-carbonyl)amino]butanoyl]amino]-3-methylbutyl]boronic acid |
| Catalog No.: | F1111 |
| Size: | 25 mg |
| CAS: | 1072833-77-2 |
| Formula: | C14H19BCl2N2O4 |
| Molecular Weight: | 361.03 g/mol |
| Form: | Lyophilized powder |
| Quality Assurance: | >98% by HPLC and NMR |
| Source: | Synthetic |
| Storage: | Eligible for room temperature shipping. Store at -20°C upon receiving; protect from air and ligh |
| PDF Data Sheet: | Download PDF datasheet， MSDS |
| Image(s): | N/A |
| Shipping Method: | Room temperature shipping |
| References: | N/A |
Details
Ixazomib (MLN2238) (commercial name: Ninlaro®) is the first and only FDA-approved oral proteasome inhibitor for the treatment of multiple myeloma. It reversibly inhibits the chymotrypsin-like activity of proteasomes with IC50 of 3.4 nM in cell-free assays, also inhibits the caspase-like and trypsin-like activities of proteasome with IC50 of 31 and 3500 nM, respectively.
Solubility:
> 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose
Solubility:
> 10 mg/ml in DMSO, < 1mg/mL in water, For in vivo use, >30 mg/mL in 0.5% hydroxyethyl cellulose
